Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DTC User Fees Rejected By House Approps Panel As FDA Safety Funds Get Boost

Executive Summary

The House Appropriations Committee opted for using federal money, rather than fees from industry, to finance speedier FDA review of direct-to-consumer television ads when it approved a $1.7 billion fiscal year 2008 funding package for the agency July 19

You may also be interested in...

FDA’s Sequestered User Fees From FY 2013 Likely Gone, But FY 2014 Fees Could Be Exempted

Rep. Farr says Congressional Budget Office scoring problems could not be overcome, meaning FY 2013 FDA user fees lost to sequester may not be recovered, but amendment will be proposed to ensure FY 2014 fees are not lost in the upcoming appropriations bill.

FDA Largely Ignored At Appropriations Subcommittee Mark-Up

Rep. DeLauro proposes only amendment, which did not affect FDA and was defeated, but also warns FDA cuts could endanger Americans’ health.

Translational Science Center Mission And Budget Draw Congress’ Scrutiny

House Appropriations subcommittee Republicans seem concerned about whether the National Center for Advancing Translational Sciences will step on industry toes, which could lead to a more tightened focus for the new NIH center’s funding in the fiscal 2013 budget.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts